Objectives: Venous thromboembolism (VTE) is a significant cause of preventable hospital-acquired mortality and of chronic venous insufficiency caused by post-thrombotic syndrome (PTS). The incidence is predicted to rise as a function of an aging and an increasingly obese population. Prevention is key in reducing VTE incidence, and is performed by using scoring systems that enable to both assess risk and determine the need for pharmacological thromboprophylaxis. The United Kingdom and United States use the Department of Health (DoH) and Caprini risk assessment scores to estimate VTE risk in their patients. The aim of this study was to assess the concordance between these two risk scores in day surgery patients.
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VTE Risk Assessment Scoring in Day Surgery Patients: U.S. and U.K. Perspectives on Risk Stratification
Sarah Onida, Monil Karia, Roshan Bootun, Alun H. Davies. Imperial College London, London, United Kingdom Objectives: Venous thromboembolism (VTE) is a significant cause of preventable hospital-acquired mortality and of chronic venous insufficiency caused by post-thrombotic syndrome (PTS). The incidence is predicted to rise as a function of an aging and an increasingly obese population. Prevention is key in reducing VTE incidence, and is performed by using scoring systems that enable to both assess risk and determine the need for pharmacological thromboprophylaxis. The United Kingdom and United States use the Department of Health (DoH) and Caprini risk assessment scores to estimate VTE risk in their patients. The aim of this study was to assess the concordance between these two risk scores in day surgery patients.
Methods: This was a prospective cohort study of patients undergoing day vascular (foam sclerotherapy, endovenous ablation, phlebectomies for superficial venous disease) and urology (cystoscopy, transurethral resection of bladder tumour/prostate) procedures at a single center. Patients were scored prior to their procedure.
Results: There were 200 vascular and 100 urology patients recruited from August to January 2015. For the vascular patients, the prerisk distribution using the DoH score was 31% (62 of 200) low risk (score 0), 33% (66 of 200) medium risk (score 1), and 36% (72 of 200) high risk (score >1). According to the Caprini scoring system, 8.5% (17 of 200) were identified as having a low risk (score 0-2), 35% (70 of 200) medium risk (score 3-4), and 56.5% (113 of 200) high/highest risk. For the urology patients, the prerisk distribution using the DoH score was 18% (18 of 100) low risk, 18% medium risk, and 64% (64 of 100) high risk. The Caprini risk assessment identified 19% (19 of 100) as low risk, 33% (33 of 100) as medium risk, and 48% (48 of 100) as high/highest risk. The level of agreement between the two scoring systems was defined as fair (Cohen k ¼ 0.267, P < .05) and moderate (Cohen k ¼ 0.571, P < .05) for patients undergoing venous and urology procedures, respectively. According to the DoH score, 69% of patients with venous disease required pharmacologic thromboprophylaxis, compared to 91.5% as assessed by the Caprini score. Approximately 80% of the urology patients required pharmacologic thromboprophylaxis according to both scores.
Conclusions: The DoH and Caprini risk assessment scores have significant differences in their low-vs medium-/high-risk stratification of patients undergoing interventions for venous disease. This finding has important clinical and cost-related implications, particularly with respect to the administration of pharmacological thromboprophylaxis. The impact of this difference and the role of these scoring systems in this patient cohort require further evaluation by means of a well-designed, large-scale, multicenter study. Objectives: The notion of long-haul flights in economy class increasing the risk of venous thromboembolic (VTE) disease in travellers has been a topic of both academic and media interest over the last few decades. This is becoming particularly important in an era where globalization and reduced airfares have resulted in >3.5 billion individuals traveling by airplane in 2016 alone. Superficial venous interventions for chronic venous disease are commonly performed and are expected to increase in number, particularly as a function of increasing age and the rising prevalence of obesity. With modern endovenous ablation techniques, the risk of VTE is estimated at <1%. However, many of these patients ask for advice regarding air travel soon after their procedure, which may put them at an increased risk of developing a VTE. The aim of this review was to assess the relationship between VTE and long-haul travel, particularly in the context of superficial venous interventions.
Methods: A review of the literature was performed searching through the PubMed and Embase databases. Search terms included [(deep vein thrombosis) 
or (deep venous thrombosis) or (venous thromboembolism)] and [(flying) or (air travel)].
Results: Significant heterogeneity exists between studies reporting VTE risk in travelers, particularly with respect to the definition of long-haul travel and the effects of immobility and hypobaric hypoxia on the coagulation system. Flight time of >4 hours, immobility, window seating, and the presence of individual VTE risk factors (eg, elevated body mass index) have been identified as risk factors for the development of travel-related VTE. An increased risk of VTE exists for at least 2 weeks following air travel. Compression stockings are advised to reduce the risk of travel related VTE in flights longer than 3 to 4 hours; however, the routine use of antiplatelet/anticoagulant agents is controversial. There are no studies regarding travel-related VTE risk in individuals following superficial venous intervention.
Conclusions: There is limited evidence regarding travel-related VTE in the context of superficial venous interventions. The existing evidence is heterogeneous and challenging to interpret. In light of the expected increase in superficial venous interventions, formal guidance is required to support physicians advising their patients regarding the risk of travel related VTE.
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Analysis of Wound-Healing Time and WoundFree Period As Outcomes After Surgical and Endovascular Revascularization for Critical Lower-Limb Ischemia
Jin Okazaki, Masaru Ishida, Kiyoshi Tanaka. Kokura Memorial Hospital, Kitakyushu-shi, Japan
Objectives: Traditional end points, such as amputation-free survival, used to assess the clinical effectiveness of lower-limb revascularization have shortcomings because they do not account independently for wound nonhealing and recurrence or patient survival. We introduced the wound-free period (WFP), the period during which limbs maintained an ulcer-free state, and the wound-existence period (WEP) as parameters and tested their effectiveness in evaluating clinical outcomes of limbs treated using endovascular therapy (EVT) and surgical revascularization.
Methods: The medical records of patients developing lower critical limb ischemia (CLI) with tissue loss who underwent surgical or endovascular revascularization of the infrainguinal vessels were retrospectively reviewed. The risk factors for achieving wound healing and wound healing time (WHT) were analyzed using Kaplan-Meier survival curves and the Cox regression model. According to the obtained significant confounding factors, matched-pair analysis comparing EVT-first and surgical revascularization (SUR)-first treatment groups were conducted. Wound healing, WHT, WFP, and WEP were compared between the groups.
Results: In total, 304 patients underwent 364 limb revascularizations, and 194 endovascular and 170 surgical procedures were performed as first treatments. The proportion of healed wounds 1, 2, and 3 years after primary revascularization was 56.3%, 63.4%, and 64.0%, respectively. Significant risk factors for wound healing were EVT-first strategy (RR, 2.13), dialysis dependence (RR, 1.70), congestive heart failure (RR, 2.02), nonambulatory status (RR, 1.74), and Wound, Ischemia, and foot Infection (WIfI) grade (RR, 2.19). The mean WHT was 158.2 days. Significant risk factors for prolonged WHT were EVT-first strategy (RR, 1.98) and WIfI grade (RR, 1.45). The mean WFP was 713.0 days. EVT-first strategy, history of coronary artery disease, dialysis dependence, and nonambulatory status were associated with significantly shorter WFPs. The matched-pair analysis showed that compared with limbs in the EVTfirst group, those in the SUR-first group showed significantly superior wound healing (60.5% vs 73.6%), WFP (407 vs 563 days), and WEP (226 vs 119 days). In the subgroup of limbs that achieved wound healing, WEPs and WHTs were significantly longer in the EVT-first group (252 and 217 days, respectively) than in the SUR group (116 and 110 days, 
